Drugs / CT7001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03363893 | Nov 2017 → Dec 2022 | high grade malignant neoplasm | Carrick Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT7001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03363893 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |
| Route | Oral | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression” NCT03363893 ↗ |